<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39328415</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.</ArticleTitle><Pagination><StartPage>1461419</StartPage><MedlinePgn>1461419</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1461419</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1461419</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Heterologous booster vaccines are more effective than homologous booster vaccines in combating the coronavirus disease 2019 (COVID-19) outbreak. However, our understanding of homologous and heterologous booster vaccines for COVID-19 remains limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We recruited 34 healthy participants from two cohorts who were primed with two-dose inactivated COVID-19 vaccine before, vaccinated with COVID-19 inactivated vaccine and adenovirus-vectored vaccine (intramuscular and aerosol inhalation of Ad5-nCoV) as a third booster dose. We assessed the immune responses of participants before and 14 days after vaccination, including levels of neutralizing antibodies, IgG, and cytokines, and quantified the transcriptional profile of peripheral blood mononuclear cells (PBMCs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The Ad5-nCoV group showed a significantly higher neutralizing antibody geometric mean titer (GMT) compared to the ICV group after 14 days of heterologous boosting. The intramuscular Ad5-nCoV group had a GMT of 191.8 (95% CI 129.0, 285.1) compared to 38.1 (95% CI 23.1, 62.8) in the ICV<sub>1</sub> group (p&lt;0.0001). The aerosolized Ad5-nCoV group had a GMT of 738.4 (95% CI 250.9-2173.0) compared to 244.0 (95% CI 135.0, 441.2) in the ICV<sub>2</sub> group (p=0.0434). Participants in the aerosolized Ad5-nCoV group had median IFN-γ+ spot counts of 36.5 (IQR 15.3-58.8) per 10<sup>6</sup> PBMCs, whereas, both intramuscular Ad5-nCoV and CoronaVac immunization as the third dose showed lower responses. This suggests that a third dose of booster Ad5-nCoV vaccine (especially aerosolized inhalation) as a heterologous vaccine booster induces stronger humoral and cellular immune responses, which may be more potent against VOCs than the use of inactivated vaccine homologs. In transcriptomic analyses, both aerosolized inhalation/intramuscular injection of the Ad5-nCoV vaccine and inactivated vaccine induced a large number of differentially expressed genes that were significantly associated with several important innate immune pathways including inflammatory responses, regulation of the defense response, and regulation of cytokine production. In addition, we identified crucial molecular modules of protective immunity that are significantly correlated with vaccine type and neutralizing antibodies level.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study demonstrated that inhalation/intramuscular injection of the Ad5-nCoV vaccine-mediated stronger humoral and cellular immune responses compared with the inactivated vaccine, and correlated significantly with innate immune function modules, supporting a heterologous booster immunization strategy.</AbstractText><CopyrightInformation>Copyright © 2024 Zheng, Li, Zheng, Jiang, Li, Yao, Li, Wang, Liu, Cao, Qi, Chen, Jin, Zhu, Li and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Cuidan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences (CAS) Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zheng</LastName><ForeName>Xiuyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Research and Development Department, CanSino Biologics Inc., Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hu-Dachuan</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Aihua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaolong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Research and Development Department, CanSino Biologics Inc., Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Feiyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research and Development Department, CanSino Biologics Inc., Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenqing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Runjie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lairun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Chinese Academy of Sciences (CAS) Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ad5-nCoV</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">aerosol inhalation</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">intramuscular injection</Keyword><Keyword MajorTopicYN="N">transcriptome</Keyword></KeywordList><CoiStatement>Author XZ, XL, and FW were employed by CanSino Biologics Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39328415</ArticleId><ArticleId IdType="pmc">PMC11424439</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1461419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO . WHO coronavirus (COVID-19) dashboard (2023). Available at: https://covid19.who.int. (Accessed May 2, 2024)</Citation></Reference><Reference><Citation>Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. (2021) 21:195–7. doi: 10.1038/s41577-021-00526-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00526-x</ArticleId><ArticleId IdType="pmc">PMC7934118</ArticleId><ArticleId IdType="pubmed">33674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. (2021) 21:475–84. doi: 10.1038/s41577-021-00578-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00578-z</ArticleId><ArticleId IdType="pmc">PMC8246128</ArticleId><ArticleId IdType="pubmed">34211186</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R, Zheng H, Wang B-S, Gou J-B, Guo X-L, Chen X-Q, et al. . Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med. (2023) 11:613–23. doi: 10.1016/S2213-2600(23)00049-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00049-8</ArticleId><ArticleId IdType="pmc">PMC9991083</ArticleId><ArticleId IdType="pubmed">36898400</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J-X, Wu S-P, Guo X-L, Tang R, Huang B-Y, Chen X-Q, et al. . Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. (2022) 10:739–48. doi: 10.1016/S2213-2600(22)00087-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00087-X</ArticleId><ArticleId IdType="pmc">PMC9122540</ArticleId><ArticleId IdType="pubmed">35605625</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. . Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. (2022) 28:401–9. doi: 10.1038/s41591-021-01677-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01677-z</ArticleId><ArticleId IdType="pmc">PMC8863573</ArticleId><ArticleId IdType="pubmed">35087233</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J-X, Hou L-H, Gou J-B, Yin Z-D, Wu S-P, Wang F-Z, et al. . Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect Dis. (2023) 23:1143–52. doi: 10.1016/S1473-3099(23)00350-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00350-X</ArticleId><ArticleId IdType="pubmed">37352880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourati S, Tomalin LE, Mulè MP, Chawla DG, Gerritsen B, Rychkov D, et al. . Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination. Nat Immunol. (2022) 23:1777–87. doi: 10.1038/s41590-022-01329-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01329-5</ArticleId><ArticleId IdType="pmc">PMC9747610</ArticleId><ArticleId IdType="pubmed">36316476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Othman R, Cai B, Liu AC, Varankovich N, He D, Blimkie TM, et al. . Systems biology methods applied to blood and tissue for a comprehensive analysis of immune response to hepatitis B vaccine in adults. Front Immunol. (2020) 11:580373. doi: 10.3389/fimmu.2020.580373</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.580373</ArticleId><ArticleId IdType="pmc">PMC7672042</ArticleId><ArticleId IdType="pubmed">33250895</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhao L, Zhang J, Zhang X, Han S, Sun Q, et al. . Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine. Immun Ageing. (2024) 21:11. doi: 10.1186/s12979-023-00408-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-023-00408-x</ArticleId><ArticleId IdType="pmc">PMC10821575</ArticleId><ArticleId IdType="pubmed">38280989</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Shin OS, Na J, Kim JK, Seong RK, Park MS, et al. . A systems vaccinology approach reveals the mechanisms of immunogenic responses to hantavax vaccination in humans. Sci Rep. (2019) 9:4760. doi: 10.1038/s41598-019-41205-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41205-1</ArticleId><ArticleId IdType="pmc">PMC6423257</ArticleId><ArticleId IdType="pubmed">30886186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcorn JF, Avula R, Chakka AB, Schwarzmann WE, Nowalk MP, Lin CJ, et al. . Differential gene expression in peripheral blood mononuclear cells from children immunized with inactivated influenza vaccine. Hum Vaccin Immunother. (2020) 16:1782–90. doi: 10.1080/21645515.2020.1711677</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1711677</ArticleId><ArticleId IdType="pmc">PMC7482876</ArticleId><ArticleId IdType="pubmed">32298194</ArticleId></ArticleIdList></Reference><Reference><Citation>Menicucci AR, Jankeel A, Feldmann H, Marzi A, Messaoudi I. Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection. mBio. (2019) 10(3):e00597-19. doi: 10.1128/mBio.00597-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00597-19</ArticleId><ArticleId IdType="pmc">PMC6538780</ArticleId><ArticleId IdType="pubmed">31138743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Knabl L, Moliva JI, Knabl L, Werner AP, Boyoglu-Barnum S, et al. . mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. Cell Rep. (2022) 39:110680. doi: 10.1016/j.celrep.2022.110680</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110680</ArticleId><ArticleId IdType="pmc">PMC8947943</ArticleId><ArticleId IdType="pubmed">35395191</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. (2014) 15:550. doi: 10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. (2008) 9:559. doi: 10.1186/1471-2105-9-559</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. (2012) 16:284–7. doi: 10.1089/omi.2011.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yao M, Guo X, Han S, Zhang S, Zhang J, et al. . Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human. Front Immunol. (2022) 13:1027180. doi: 10.3389/fimmu.2022.1027180</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1027180</ArticleId><ArticleId IdType="pmc">PMC9634958</ArticleId><ArticleId IdType="pubmed">36341453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmers F, Donato M, Kuo A, Ashuach T, Gupta S, Li C, et al. . The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell. (2021) 184:3915–3935 e21. doi: 10.1016/j.cell.2021.05.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.039</ArticleId><ArticleId IdType="pmc">PMC8316438</ArticleId><ArticleId IdType="pubmed">34174187</ArticleId></ArticleIdList></Reference><Reference><Citation>Afkhami S, D’Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, et al. . Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. (2022) 185:896–915.e19. doi: 10.1016/j.cell.2022.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8825346</ArticleId><ArticleId IdType="pubmed">35180381</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Xu M, Yang J, Zhou L, Liu L, Li M, et al. . Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1. Sig Transduct Target Ther. (2024) 9:114. doi: 10.1038/s41392-024-01822-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01822-3</ArticleId><ArticleId IdType="pmc">PMC11055866</ArticleId><ArticleId IdType="pubmed">38678055</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Vega M, Wan H, Reséndiz-Sandoval M, Hinojosa-Trujillo D, Valenzuela O, Mata-Haro V, et al. . Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines. Genes Immun. (2024) 25:158–67. doi: 10.1038/s41435-024-00270-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41435-024-00270-x</ArticleId><ArticleId IdType="pubmed">38570727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Wu S, Xiao C, Chen S, Chi X, Cui X, et al. . Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. Cell Discovery. (2021) 7:64. doi: 10.1038/s41421-021-00300-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00300-2</ArticleId><ArticleId IdType="pmc">PMC8352953</ArticleId><ArticleId IdType="pubmed">34373443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC, et al. . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. (2012) 18:274–80. doi: 10.1038/nm.2612</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2612</ArticleId><ArticleId IdType="pubmed">22286307</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralambieva IH, Oberg AL, Ovsyannikova IG, Kennedy RB, Grill DE, Middha S, et al. . Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. PloS One. (2013) 8:e62149. doi: 10.1371/journal.pone.0062149</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062149</ArticleId><ArticleId IdType="pmc">PMC3641062</ArticleId><ArticleId IdType="pubmed">23658707</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, et al. . Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity. (2013) 38:831–44. doi: 10.1016/j.immuni.2012.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.12.008</ArticleId><ArticleId IdType="pmc">PMC3681204</ArticleId><ArticleId IdType="pubmed">23601689</ArticleId></ArticleIdList></Reference><Reference><Citation>Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. . Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. (2009) 10:116–25. doi: 10.1038/ni.1688</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1688</ArticleId><ArticleId IdType="pmc">PMC4049462</ArticleId><ArticleId IdType="pubmed">19029902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>